Abstract
Remote monitoring of patients treated with cardiac implantable electronic devices is a medical service known for more than two decades. Its efficacy has been proven in numerous clinical trials and the benefits of remote monitoring could not be overestimated during the COVID-19 pandemic. The telemonitoring of implanted devices, in addition to receiving and analyzing acquired data, should also provide effective action to protect patients from the occurrence of clinical events caused by a potential risk of heart failure deterioration or a system malfunction. The article discusses the main rules of the remote monitoring implementation contained in the Ministry of Health draft regulation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
